Ipsen UK & Ireland Launches New Pre-filled Syringe for Somatuline® Autogel® (lanreotide)

Ipsen Launches Syringe Somatuline Autogel

UK patients and healthcare professionals involved in the re-design of pre-filled syringe to meet the needs and expectations of patients.

The UK affiliate of Ipsen (Euronext: IPN; ADR: IPSEY) announced the launch of a new pre-filled syringe for Somatuline® Autogel® (lanreotide). Results from five separate studies, involving patients and healthcare professionals have informed the redesign of the lanreotide syringe.

This patient-centred research has enabled the development, testing and validation of the syringe, which is intended to enable patients to have more control of their disease by supporting self or partner injection, and potentially requiring fewer hospital visits.

The syringe is now available for use on the NHS for the treatment of adult patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs), symptoms associated with neuroendocrine (particularly carcinoid) tumours (NETs), and acromegaly.

Over 4,000 people are diagnosed with a NET each year in the UK and although once considered rare, the incidence of NETs is on the rise. Survival rates have improved over the last decade and so patients are living for longer with the disease. However, living with NETs has a considerable impact on patients’ personal and work lives and data suggest there is a need to improve the patient experience. Acromegaly is a rare hormone disorder resulting in an overgrowth of all organ systems, bones, joints and soft tissues. The incidence in Europe is around 2-4 per million population and its prevalence estimates range from 36 to 60 per million.

New features include modified ergonomics and handling, a needle shield removal system, an injection process with plunger support and a thermoform tray to prevent accidental plunger depression. The automatic, built-in safety system, which helps to prevent needle stick injury by locking in place following the administration, has not been changed. The mode of administration of lanreotide with the new pre-filled syringe remains the same (i.e. deep subcutaneous injection).

Wendy Martin, NET Clinical Nurse Specialist at Kings College London and Lead Investigator said “We can genuinely discuss independence for patients living with these chronic, burdensome disease. Patients want and need treatment options that allow them as much freedom and flexibility as possible so that they can live fuller lives and spend, what is for them precious time with family and friends. I hope that today’s development can transform NET clinics across the UK and further enhance patient care.”